Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

6

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Retinoic acid receptor gamma

7

Retinoic acid receptor

6

Retinoic acid receptor beta

6

Retinoid X receptor alpha

6

Retinoid X receptor gamma

6

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1971

6

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

AIDS-related Kaposi’s sarcoma

6

Acne vulgaris

6

Acute promyelocytic leukemia

6

severe recalcitrant nodular acne

6

Breast cancer

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

7

Palliative

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Ligand Pharmaceuticals

6

Allergan

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

7

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

7

EPA CompTox

7

FDA UNII

7

PUBCHEM

7

CHEBI

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

DERMATOLOGICALS

3

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTI-ACNE PREPARATIONS

2

ANTINEOPLASTIC AGENTS

2

OTHER DERMATOLOGICAL PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTI-ACNE PREPARATIONS FOR TOPICAL USE

2

OTHER ANTINEOPLASTIC AGENTS

2

ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE

1

OTHER DERMATOLOGICAL PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other antineoplastic agents

2

Retinoids for topical use in acne

2

Agents for dermatitis, excluding corticosteroids

1

Other dermatologicals

1

Retinoids for treatment of acne

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Tretinoin

5688UTC01R

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

AROTINOID ACID

673M8C29UR

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoid X receptor beta

Retinoic acid receptor alpha

Retinoic acid receptor gamma

Conditions:

Pancreatic cancer

Prostate cancer

Arotinoid acid (Ro 13-7410, TTNPB) is the third generation of synthetic retinoid, which was developed for the treatment of psoriasis and other hyperkeratotic skin disorders. The therapeutically active dose is less than 0.5 ug/kg body weight/day. Arot...

inoid Acid is an agonist of RAR with IC50 values of 3.8nM, 4nM and 4.5nM for RARα, RARβ and RARγ, respectively. Naturally occurring vitamin A-like compounds such as all-trans-retinoic acid (atRA) are responsible for regulating growth and differentiation in the cell, and many of them have shown promising anticancer effects. Bioassays in vivo and in culture showed that TTNPB is more potent than atRA, mainly because of its higher molecular stability. The effects of TTNPB, which include control of epidermal keratinocytes and murine teratocarcinoma cells and antiproliferative effects on Kaposi´s sarcoma, breast cancer, cervical carcinoma, and leukemia cells have been known for some time. Furthermore, TTNPB proved to be 100 times more effective than atRA in inhibiting the growth of breast cancer cells. However, TTNPB is more teratogenic than atRA, which limits its use as a chemotherapeutic agent in humans. Arotinoid acid (AGN193198) has being shown to be useful for the treatment of pancreatic cancer among other types of cancer.

Alitretinoin

1UA8E65KDZ

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

TRETINOIN ZINC

7A9179CU3G

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

SODIUM RETINOATE

DD7YX785YA

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

ISOTRETINOIN ANISATIL

922SI67369

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

Isotretinoin

EH28UP18IF

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1